Skip to main content

SDGR

Stock
Health Care
Health Information Services

Performance overview

SDGR Price
Price Chart

Forward-looking statistics

Beta
1.21
Risk
61.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Company info

SectorHealth Care
IndustryHealth Information Services
Employees844
Market cap$1.6B

Fundamentals

Enterprise value$1.1B
Revenue$230.5M
Revenue per employee
Profit margin-83.39%
Debt to equity31.15

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.63
Dividend per share
Revenue per share$3.16
Avg trading volume (30 day)$22M
Avg trading volume (10 day)$18M
Put-call ratio

Macro factor sensitivity

Growth+0.8
Credit+15.9
Liquidity-5.7
Inflation-3.5
Commodities+0.6
Interest Rates-2.6

Valuation

Dividend yield0.00%
PEG Ratio-8.37
Price to sales6.58
P/E Ratio-8.37
Enterprise Value to Revenue4.74
Price to book4.06

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.

CNBC Television (May 28, 2025)
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Zacks Investment Research (May 27, 2025)
The Good And Bad: Allison Transmission & Schrodinger Inc.

See two of the featured stocks from this month's model portfolios.

Forbes (September 21, 2023)
BofA Downgrades Schrodinger On Slower Drug Discovery Ramp

Schrodinger Inc (NASDAQ:SDGR) reported downbeat third-quarter results, mainly due to lower-than-expected drug discovery revenues, according to BofA Securities. The Schrodinger Analyst: Michael Ryskin downgraded Schrodinger from Buy to Neutral and lowered the price target from $80 to $52.

Benzinga (November 11, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free